Ambea (AMBEA) M&A announcement summary
Event summary combining transcript, slides, and related documents.
M&A announcement summary
29 Jun, 2026Deal rationale and strategic fit
The combination creates a leading Nordic care provider with a broader platform, specialist capabilities, and a strong geographical footprint across all major Nordic markets, addressing growing demand due to aging populations and increased care needs.
Both organizations share a commitment to high-quality, individualized, and sustainable care, providing a strong cultural foundation for integration and long-term value creation.
The deal enables accelerated investment in care methods, digital tools, AI, and innovation to meet growing care needs and future success.
Complementary strengths broaden expertise, specialist capabilities, and geographical footprint, with enhanced opportunities for knowledge sharing and employee development.
Ambea intends to divest Humana's Swedish Personal Assistance business post-merger to focus on core operations.
Financial terms and conditions
Humana shareholders are offered SEK 62.30 per share, consisting of SEK 20 in cash, 0.305 Ambea shares per Humana share, and a contingent value right (CVR) up to 4.36 SEK per share.
The offer values Humana at approximately SEK 2.96 billion, representing a 26.8% premium to the prior closing price, 24.0% to 30-day VWAP, and 31.8% to 90-day VWAP.
Including the full CVR payout, the offer could reach approximately SEK 3,168 million plus litigation cost compensation and interest.
The acquisition will be financed through cash, buybacks, newly issued shares, incremental financing from existing lenders, and debt, with no financing condition for completion.
Supported by Humana’s board and major shareholders representing 41.9% of capital and votes, with an additional 3.4% expressing support.
Synergies and expected cost savings
Annual run-rate pre-tax cost synergies of approximately SEK 120 million are expected, fully realized in the second year post-completion.
Synergies will come from overlapping group functions, reduced administrative costs, operational improvements, and more effective use of joint resources.
One-off transaction and integration costs are expected primarily in the first 12-15 months after completion, estimated at SEK 150 million.
Transaction-related costs are estimated at SEK 90 million in 2026.
Cost synergies alone represent about 0.5 percentage point EBITDA margin improvement.
Latest events from Ambea
- Strong sales and earnings growth, margin expansion, and a SEK 2.20 dividend proposed.AMBEA
Q4 202418 May 2026 - Strong Q2 with 42% EBITA/EBITDA growth, robust cash flow, and continued expansion through M&A.AMBEA
Q2 202418 May 2026 - Q1 2026 delivered 16% sales growth, margin gains, and strong expansion across all Nordic segments.AMBEA
Q1 20267 May 2026 - 15% sales growth, robust cash flow, and a 20% dividend increase proposed.AMBEA
Q4 202517 Apr 2026 - Q3 2024 delivered 6% sales growth, 25% EBITA rise, and strong cash flow for expansion.AMBEA
Q3 202416 Jan 2026 - Acquisition creates the only pan-Nordic care group, expanding into Finland and boosting growth.AMBEA
M&A Announcement26 Dec 2025 - Q1 2025 saw 5% sales growth, Validia acquisition, and strong cash flow for Nordic expansion.AMBEA
Q1 202526 Nov 2025 - Q2 2025 saw 16% sales growth, 15% EBITA rise, and all financial targets achieved.AMBEA
Q2 202523 Nov 2025 - Q3 net sales up 16% and adjusted EBITA up 19%, driven by Nordic growth and acquisitions.AMBEA
Q3 20255 Nov 2025